Adamas Pharmaceuticals reported results from the phase 3 INROADS study, which evaluated ADS-5102 in multiple sclerosis (MS) patients with walking impairment. The trial met the primary endpoint but failed to meet secondary objectives INROADS was a 12-week,...
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
159 WEST BROADWAY SUITE 200 SALT LAKE CITY, UT 84101
Pin It on Pinterest